Trials / Unknown
UnknownNCT02327702
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant chronic hepatitis B patients. Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery.
Detailed description
Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery, which include HBeAg positive and negative patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emtricitabine | emtricitabine were given to each patients at baseline till 48 weeks after delivery |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-07-01
- Completion
- 2017-07-01
- First posted
- 2014-12-30
- Last updated
- 2014-12-30
Source: ClinicalTrials.gov record NCT02327702. Inclusion in this directory is not an endorsement.